Annual CFF
$15.06 M
-$5.38 M-26.33%
December 31, 2023
Summary
- As of February 7, 2025, BLRX annual cash flow from financing activities is $15.06 million, with the most recent change of -$5.38 million (-26.33%) on December 31, 2023.
- During the last 3 years, BLRX annual CFF has fallen by -$2.81 million (-15.73%).
- BLRX annual CFF is now -73.93% below its all-time high of $57.75 million, reached on December 31, 2021.
Performance
BLRX Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
-$1.22 M
-$25.10 M-105.10%
September 1, 2024
Summary
- As of February 7, 2025, BLRX quarterly cash flow from financing activities is -$1.22 million, with the most recent change of -$25.10 million (-105.10%) on September 1, 2024.
- Over the past year, BLRX quarterly CFF has dropped by -$4.72 million (-134.81%).
- BLRX quarterly CFF is now -102.91% below its all-time high of $41.91 million, reached on March 31, 2021.
Performance
BLRX Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$33.51 M
-$4.72 M-12.34%
September 1, 2024
Summary
- As of February 7, 2025, BLRX TTM cash flow from financing activities is $33.51 million, with the most recent change of -$4.72 million (-12.34%) on September 1, 2024.
- Over the past year, BLRX TTM CFF has increased by +$30.84 million (+1155.41%).
- BLRX TTM CFF is now -48.07% below its all-time high of $64.52 million, reached on September 30, 2021.
Performance
BLRX TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
BLRX Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -26.3% | -134.8% | +1155.4% |
| 3 y3 years | -15.7% | -177.3% | -48.1% |
| 5 y5 years | +15.0% | -177.3% | -48.1% |
BLRX Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -73.9% | at low | -105.1% | at low | -42.0% | >+9999.0% |
| 5 y | 5-year | -73.9% | at low | -102.9% | at low | -48.1% | >+9999.0% |
| alltime | all time | -73.9% | >+9999.0% | -102.9% | at low | -48.1% | >+9999.0% |
BioLineRx Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$1.22 M(-105.1%) | $33.51 M(-12.3%) |
| Jun 2024 | - | $23.88 M(-2771.0%) | $38.22 M(+169.0%) |
| Mar 2024 | - | -$894.00 K(-107.6%) | $14.21 M(-5.6%) |
| Dec 2023 | $15.06 M(-26.3%) | $11.74 M(+235.5%) | $15.06 M(+464.1%) |
| Sep 2023 | - | $3.50 M(-2711.2%) | $2.67 M(-87.8%) |
| Jun 2023 | - | -$134.00 K(+173.5%) | $21.89 M(+2.6%) |
| Mar 2023 | - | -$49.00 K(-92.4%) | $21.33 M(+4.4%) |
| Dec 2022 | $20.44 M(-64.6%) | -$647.00 K(-102.8%) | $20.44 M(-3.9%) |
| Sep 2022 | - | $22.72 M(-3397.1%) | $21.26 M(>+9900.0%) |
| Jun 2022 | - | -$689.00 K(-26.9%) | $117.00 K(-99.2%) |
| Mar 2022 | - | -$943.00 K(-642.0%) | $14.90 M(-74.2%) |
| Dec 2021 | $57.75 M(+223.2%) | $174.00 K(-89.0%) | $57.75 M(-10.5%) |
| Sep 2021 | - | $1.57 M(-88.8%) | $64.52 M(+4.2%) |
| Jun 2021 | - | $14.09 M(-66.4%) | $61.90 M(+4.2%) |
| Mar 2021 | - | $41.91 M(+503.2%) | $59.39 M(+232.4%) |
| Dec 2020 | $17.87 M(-6.9%) | $6.95 M(-762.9%) | $17.87 M(+32.2%) |
| Sep 2020 | - | -$1.05 M(-109.1%) | $13.51 M(-12.5%) |
| Jun 2020 | - | $11.58 M(+2892.2%) | $15.44 M(+231.0%) |
| Mar 2020 | - | $387.00 K(-85.1%) | $4.66 M(-75.7%) |
| Dec 2019 | $19.19 M(+46.6%) | $2.59 M(+194.9%) | $19.19 M(-28.6%) |
| Sep 2019 | - | $879.00 K(+9.1%) | $26.88 M(+3.3%) |
| Jun 2019 | - | $806.00 K(-94.6%) | $26.02 M(-2.2%) |
| Mar 2019 | - | $14.92 M(+45.1%) | $26.61 M(+103.2%) |
| Dec 2018 | $13.10 M(-66.1%) | $10.28 M(>+9900.0%) | $13.10 M(+244.0%) |
| Sep 2018 | - | $18.00 K(-98.7%) | $3.81 M(-71.2%) |
| Jun 2018 | - | $1.40 M(0.0%) | $13.21 M(-65.2%) |
| Mar 2018 | - | $1.40 M(+41.6%) | $38.02 M(-1.7%) |
| Dec 2017 | $38.68 M | $989.00 K(-89.5%) | $38.68 M(+1.1%) |
| Sep 2017 | - | $9.43 M(-64.0%) | $38.26 M(+32.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2017 | - | $26.20 M(+1169.4%) | $28.81 M(+1015.7%) |
| Mar 2017 | - | $2.06 M(+264.7%) | $2.58 M(+23.5%) |
| Dec 2016 | $2.09 M(-92.9%) | $566.00 K(-2560.9%) | $2.09 M(+22.2%) |
| Sep 2016 | - | -$23.00 K(-8.0%) | $1.71 M(-28.5%) |
| Jun 2016 | - | -$25.00 K(-101.6%) | $2.39 M(-48.0%) |
| Mar 2016 | - | $1.57 M(+745.2%) | $4.60 M(-84.4%) |
| Dec 2015 | $29.49 M(-9.6%) | $186.00 K(-71.7%) | $29.49 M(-25.0%) |
| Sep 2015 | - | $658.00 K(-69.9%) | $39.33 M(+1.7%) |
| Jun 2015 | - | $2.19 M(-91.7%) | $38.67 M(+6.0%) |
| Mar 2015 | - | $26.46 M(+164.0%) | $36.48 M(+11.8%) |
| Dec 2014 | $32.63 M(+116.5%) | $10.02 M(>+9900.0%) | $32.63 M(+37.9%) |
| Sep 2014 | - | $0.00(-100.0%) | $23.67 M(-5.6%) |
| Jun 2014 | - | $2000.00(-100.0%) | $25.08 M(-4.2%) |
| Mar 2014 | - | $22.61 M(+2039.3%) | $26.18 M(+73.7%) |
| Dec 2013 | $15.07 M(-4.4%) | $1.06 M(-25.3%) | $15.07 M(-8.8%) |
| Sep 2013 | - | $1.41 M(+28.3%) | $16.53 M(+10.1%) |
| Jun 2013 | - | $1.10 M(-90.4%) | $15.00 M(+13.9%) |
| Mar 2013 | - | $11.50 M(+358.4%) | $13.17 M(-16.5%) |
| Dec 2012 | $15.77 M(<-9900.0%) | $2.51 M(-2446.9%) | $15.77 M(+19.1%) |
| Sep 2012 | - | -$106.90 K(-85.4%) | $13.24 M(-0.7%) |
| Jun 2012 | - | -$732.80 K(-105.2%) | $13.33 M(-5.1%) |
| Mar 2012 | - | $14.10 M(<-9900.0%) | $14.04 M(<-9900.0%) |
| Dec 2011 | -$80.70 K(-137.4%) | -$19.50 K(+14.0%) | -$80.70 K(+16.8%) |
| Sep 2011 | - | -$17.10 K(-24.7%) | -$69.10 K(+16.3%) |
| Jun 2011 | - | -$22.70 K(+6.1%) | -$59.40 K(-130.6%) |
| Mar 2011 | - | -$21.40 K(+170.9%) | $194.20 K(-9.9%) |
| Dec 2010 | $215.60 K | -$7900.00(+6.8%) | $215.60 K(-3.5%) |
| Sep 2010 | - | -$7400.00(-103.2%) | $223.50 K(-3.2%) |
| Jun 2010 | - | $230.90 K(>+9900.0%) | $230.90 K(>+9900.0%) |
| Mar 2010 | - | $0.00 | $0.00 |
FAQ
- What is BioLineRx annual cash flow from financing activities?
- What is the all time high annual CFF for BioLineRx?
- What is BioLineRx annual CFF year-on-year change?
- What is BioLineRx quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for BioLineRx?
- What is BioLineRx quarterly CFF year-on-year change?
- What is BioLineRx TTM cash flow from financing activities?
- What is the all time high TTM CFF for BioLineRx?
- What is BioLineRx TTM CFF year-on-year change?
What is BioLineRx annual cash flow from financing activities?
The current annual CFF of BLRX is $15.06 M
What is the all time high annual CFF for BioLineRx?
BioLineRx all-time high annual cash flow from financing activities is $57.75 M
What is BioLineRx annual CFF year-on-year change?
Over the past year, BLRX annual cash flow from financing activities has changed by -$5.38 M (-26.33%)
What is BioLineRx quarterly cash flow from financing activities?
The current quarterly CFF of BLRX is -$1.22 M
What is the all time high quarterly CFF for BioLineRx?
BioLineRx all-time high quarterly cash flow from financing activities is $41.91 M
What is BioLineRx quarterly CFF year-on-year change?
Over the past year, BLRX quarterly cash flow from financing activities has changed by -$4.72 M (-134.81%)
What is BioLineRx TTM cash flow from financing activities?
The current TTM CFF of BLRX is $33.51 M
What is the all time high TTM CFF for BioLineRx?
BioLineRx all-time high TTM cash flow from financing activities is $64.52 M
What is BioLineRx TTM CFF year-on-year change?
Over the past year, BLRX TTM cash flow from financing activities has changed by +$30.84 M (+1155.41%)